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SDM was identiﬁed as a strong independent predictor of stroke (HR ¼3.09; 95% CI
1.52-6.29, p¼0.002), TLR (HR¼2.10; 95% CI 1.30-3.38, p¼0.002) and TVR
(HR ¼1.66; 95% CI 1.15-2.39, p¼0.006).
Conclusions: Among this large series of consecutives pts undergoing LM PCI, DM
was not associated with an increase in death or ST, but was independently predictive
of stroke, TVR and TLR at 6-year follow-up.
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Background: Patients with severe left ventricular (LV) dysfunction undergoing
intervention (PCI) upon the unprotected left main coronary (ULM) or the last
remaining conduit (LRC) are susceptible to peri-procedural heart failure or hypoten-
sion which may limit the effectiveness of revascularization efforts.
Methods: The Protect II trial compared an LV assist device (Impella 2.5) to intra-
aortic balloon counterpulsation (IABP) in patients undergoing high risk coronary
intervention. We analyzed 90 day outcomes from the subset of study subjects treated
with ULM or LRC intervention.
Results: A total of 448 patients were treated in the Protect II trial and of these 102
underwent ULM (34 Impella, 35 IABP) or another LRC (15 impella, 18 IABP) PCI
per protocol deﬁnition. Of the ULM/LRC cohort (N¼ 102), 50% had class 3 or 4 heart
failure, and the mean LVEF was 26%. Procedural differences between the two groups
included a trend for more use of rotational atherectomy (RA), (22.4% vs 9.4%,
p¼0.071) with Impella; when RA was used, patients on Impella were treated with
longer atherectomy runs (94.1 vs 36.5 sec, p¼0.026). Duration of device support was
much shorter (1.6 vs 10.8 hours, p¼0.013) with Impella compared to IABP.
Comparing 90 day composite major adverse cardiac and cerebrovascular events
(MACCE) of death, large myocardial infarction (MI) with CK-MB > 8x normal,
stroke, or repeat revascularization procedures, Impella use was associated with less
MACCE compared to IABP use (16.7% vs 34.0%; p¼0.047). The difference in
MACCE was mainly driven by fewer strokes (0% vs 5.7%) and repeat procedures (0%
vs 11.3%) with Impella.
Conclusions: In this subgroup analysis of a randomized trial, in patients with severe
LV dysfunction undergoing PCI to the ULM or LRC, the use of Impella LV assist
during intervention was associated with a lower risk of major adverse events at 90
days compared to the use of a IABP.
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Background: Recently, the SYNTAX score-2 (SxS-2) was developed in an attempt to
individualize and help the decision-making process between percutaneous coronary
intervention (PCI) and coronary artery bypass graft (CABG) in the management of
complex coronary artery disease (CAD). We sought to evaluate and conﬁrm the
prognostic capacity of the SxS-2 among a group of 1,528 consecutive patients who
already underwent left main (LM) PCI.
Methods: Data from all consecutive patients from a single center undergoing LM PCI
were prospectively collected. Coronary angiograms and the resulting SYNTAX scores
(SxS)/residual SxS were assessed by an independent angiographic core laboratory,
and then the SxS-II derived for both PCI and CABG using patients' baseline clinical
characteristics. Patients were divided and compared according to whether the SxS-II
indicated PCI vs. CABG as the most favorable strategy of revascularization. Cumu-
lative adverse ischemic outcomes, including death, were compared between the 2
groups.
Results: Among the study population of 1528 patients, 238 patients (15.6%) were
deemed to be better candidates for CABG. Baseline and residual SxS were higher in
CABG group compared with the PCI group (26.38.1 vs. 23.56.8, p<0.0001 and
6.07.4 vs. 4.15.5, p¼0.0001, respectively). At a mean follow-up of 4.4 years, the
CABG group had a non-signiﬁcant trend toward higher death (6.7% vs. 4.7%,
p¼0.21), mainly driven by cardiac death (5.0% vs. 2.7%, p¼0.07), and increased
myocardial infarction (11.3% vs. 6.8%, p¼0.02). Multivariate analysis showed CABG
preference based on SxS-II to be an independent predictor of mortality (HR¼4.13;
[95% CI] [1.59, 10.7] p¼0.004) after LM PCI.
Conclusions: Results from this large series of consecutive patients who underwent
LM PCI retrospectively conﬁrmed the prognostic capability of the SxS-II for mortality
among patients with complex coronary artery disease.B130 JACC Vol 62/18/Suppl B j October 27–November 1, 2TCT-419
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Background: Background: The DESolve novolimus-eluting bioresorbable
scaffold system (Elixir Medical Co., Sunnyvale, CA) is a novel bioresorbable
vascular scaffold device that combines a PLLA-based scaffold (strut thickness 150
mm) coated with a potent antiproliferative sirolimus metabolite – Novolimus (5
mm per mm of scaffold length). Our aim was to investigate the occurrence of side
branch (SB) compromise after implantation of the DESolve device in single de
novo coronary lesions
Methods: Methods: 126 patients/lesions were prospectively enrolled in the multi-
center (13 sites), non-randomized, single-arm DESolve Nx trial. Lesion criteria were
< 14 mm in length located in a native coronary vessel measuring 2.75-3.5 mm in
diameter. SB compromise, deﬁned as vessel occlusion (TIMI ﬂow 0/1) at post-
procedure, was evaluated within the treated segment covered by the study device at an
independent angiographic core laboratory. All SBs >1.0 mm in diameter (by visual
estimation) were considered for analysis.
Results: Results: Overall, there were 71 SBs >1.0 mm found in 123 coronary
segments treated by 126 scaffolds (3 lesions did not receive the study device; 3 lesions
received 2 study devices). The majority of SBs (96%) had pre-procedure TIMI 3 ﬂow.
During the procedure, neither guide wire protection nor intervention was performed in
any SB. At post-procedure, SB occlusion was detected in only 3 cases, representing
a 4.2% SB compromise rate. Importantly, there were no adverse clinical events during
hospitalization associated with SB occlusion.
Conclusions: Conclusions: In the prospective, non-randomized, single-arm, multi-
center DESolve Nx trial, SB compromise – as determined by vessel occlusion after
implantation of the novel DESolve bioresorbable vascular scaffold, was relatively low
(4.2%) and was not associated with adverse clinical events during index hospitalization.TCT-420
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Background: Randomized controlled trials have demonstrated that of second-
generation drug-eluting stents (DES) for the treatment of obstructive coronary artery
disease is associated with comparable, if not improved, clinical outcomes as compared
to that of their ﬁrst-generation counterparts. The aim of this study was to compare the
long-term clinical outcomes associated with ﬁrst- versus second-generation DES for
the treatment of coronary bifurcation lesions.
Methods: This was a retrospective study of consecutive de novo bifurcation lesions,
excluding those at the left main, treated with either second-generation DES (ever-
olimus-eluting or zotarolimus-eluting stents) between October 2006-October 2011
(199 bifurcation lesions in 192 patients) or ﬁrst-generation DES (sirolimus-eluting or
paclitaxel-eluting stents) between April 2002-December 2005 (289 bifurcation lesions
in 273 patients).
Results: Second-generation DES use in this setting was associated with less major
adverse cardiac events (MACE) (23.1% vs. 14.4%, p¼ 0.02) as well as lower target
vessel revascularization (TVR) rates (15.5% vs. 8.3%, p¼0.01) at 2-year follow-up.
Target lesion revascularization, both per patient (12.6% vs. 7.4%, p¼0.02) and per
bifurcation (11.8% vs. 7.0%, p¼0.03), was also improved with second-generation
DES over the same follow-up period. Propensity-score adjusted analysis suggested
than ﬁrst-generation DES was an independent predictor of both MACE (HR, 0.53;
95% CI, 0.33-0.85; p¼0.01) and TVR (HR, 0.44; 95% CI, 0.24-0.83; p¼0.01).
Conclusions: Our results suggest that the use of second-generation DES for the
treatment of bifurcation lesions is associated with better clinical outcomes as compared
to ﬁrst-generation DES, largely due to a lower need for repeat revascularization.013 j TCT Abstracts/POSTER/Bifurcation and Left Main Interventions
